Lack of analgesic activity of morphine-6-glucuronide after short-term intravenous administration in healthy volunteers

Anesthesiology

Volumn 87, Issue 6, 1997, Pages 1348-1358

  Lötsch, Jörn ^a   Kobal, Gerd ^b   Stockmann, Anne ^b   Brune, Kay ^b   Geisslinger, Gerd ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b NONE

Author keywords

Analgesia; Analgesics; Evoked potentials; Intravenous; Morphine; Morphine 6 glucuronide; Pharmacokinetics; Steady state

Indexed keywords

MORPHINE; MORPHINE 6 GLUCURONIDE; PLACEBO;

ADULT; ANALGESIC ACTIVITY; ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PAIN ASSESSMENT; PRIORITY JOURNAL;

ADULT; ANALGESIA; ANALGESICS, OPIOID; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MORPHINE; MORPHINE DERIVATIVES; PAIN; PAIN MEASUREMENT; TIME FACTORS;

EID: 0345368078     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-199712000-00014     Document Type: Article

References (70)

1. Paul D, Standifer KM, Inturrisi CE, Pasternak GW: Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 1989; 251:477-83
2. Frances B, Gout R, Monsarrat B, Cros J, Zajac JM: Further evidence that morphine-6 beta-glucuronide is a more potent opioid agonist than morphine. J Pharmacol Exp Ther 1992; 262:25-31
3. Stain F, Barjavel MJ, Sandouk P, Plotkine M, Scherrmann JM, Bhargava HN: Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D-glucuronide in the rat. J Pharmacol Exp Ther 1995; 247:852-7
4. Shimomura K, Kamata O, Ueki S, Ida S, Oguri K: Analgesic effect of morphine glucuronides. Tohoku J Exp Med 1971; 105:45-52
5. Kamata O, Watanabe S, Ishii S, Ueki S, Oguri K, Ida S, Yoshimura H, Tsukamoto H: Analgesic effect of morphine glucuronides, Proceeding of the 89th Meeting Pharmacology Society of Japan, 1969, pp 443
6. Yoshimura H, Ida S, Oguri K, Tsukamoto H: Biochemical basis for analgesic activity of morphine-6-glucuronide. I. Penetration of morphine-6-glucuronide in the brain of rats. Biochem Pharmacol 1973; 22:1423-30
7. Gong QL, Hedner T, Hedner J, Bjorkman R, Nordberg G: Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide. Eur J Pharmacol 1991; 193:47-56
8. Sullivan AF, McQuay HJ, Bailey D, Dickenson AH: The spinal antinociceptive actions of morphine metabolites morphine-6-glucuronide and normorphine in the rat. Brain Res 1989; 482:219-24
9. Frances B, Gout R, Campistron G, Panconi E, Cros J: Morphine-6-glucuronide is more mu-selective and potent in analgesic tests than morphine. Prog Clin Biol Res 1990; 328:477-80
10. Gong QL, Hedner J, Bjorkman R, Hedner T: Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain 1992; 48:249-55
11. Abbott FV, Palmour RM: Morphine-6-glucuronide: Analgesic effects and receptor binding profile in rats. Life Sci 1988; 43(21):1685-95
12. Hand CW, Blunnie WP, Claffey LP, McShane AJ, McQuay HJ, Moore RA: Potential analgesic contribution from morphine-6-glucuronide in CSF [Letter]. Lancet 1987; 2:1207-8
13. Portenoy RK, Thaler HT, Inturrisi CE, Friedlander Klar H, Foley KM: The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin Pharmacol Ther 1992; 51:422-31
14. Hasselstrom J, Berg U, Lofgren A, Sawe J: Long lasting respiratory depression induced by morphine-6-glucuronide? Br J Clin Pharmacol 1989; 27:515-8
15. Tiseo PJ, Thaler HT, Lapin J, Inturrisi CE, Portenoy RK, Foley KM: Morphine-6-glucuronide concentrations and opioid-related side effects: A survey in cancer patients. Pain 1995; 61:47-54
16. Mostert JW, Evers JL, Hobika GH, Moore RH, Ambrus JL: Cardiorespiratory effects of anaesthesia with morphine or fentanyl in chronic renal failure and cerebral toxicity after morphine. Br J Anaesth 1971; 43:1053-60
17. Don HF, Dieppa RA, Taylor P: Narcotic analgesics in anuric patients. ANESTHESIOLOGY 1975; 42:745-7
18. Portenoy RK, Foley KM, Stulman J, Khan E, Adelhardt J, Layman M, Cerbone DF, Inturrisi CE: Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: Plasma profiles, steady-state concentrations and the consequences of renal failure. Pain 1991; 47:13-9
19. Hagen NA, Foley KM, Cerbone DJ, Portenoy RK, Inturrisi CE: Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manage 1991; 6:125-8
20. Osborne RJ, Joel SP, Slevin ML: Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J Clin Res Ed 1986; 292:1548-9
21. Sear JW, Hand CW, Moore RA, McQuay HJ: Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites. Br J Anaesth 1989; 62:28-32
22. Bodd E, Jacobsen D, Lund E, Ripel A, Morland J, Wiik Larsen E: Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure. Hum Exp Toxicol 1990; 9:317-21
23. Milne RW, Nation RL, Somogyi AA, Bochner F, Griggs WM: The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. Br J Clin Pharmacol 1992; 34:53-9
24. Osborne R, Joel S, Grebenik K, Trew D, Slevin M: The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther 1993; 54:158-67
25. Hanna MH, D'Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, Davies S: Morphine-6-glucuronide disposition in renal impairment. Br J Anaesth 1993; 70:511-4
26. Peat SJ, Hanna MH, Woodham M, Knibb AA, Ponte J: Morphine-6-glucuronide: effects on ventilation in normal volunteers. Pain 1991; 45:101-4
27. Thompson PI, John L, Wedzicha JA, Slevin ML: Comparison of the respiratory depression induced by morphine and morphine-6-glucuronide. Br J Cancer 1990; 62:484
28. Thompson P, Joel S, John L, MacLean M, Slevin M: Respiratory depression following morphine and morphine-6-glucuronide in normal subjects. Br J Clin Pharmacol 1995; 40:145-52
29. Lötsch J, Stockmann A, Kobal G, Brune K, Waibel R, Schmidt N, Geisslinger G: Pharmacokinetics of morphine and its glucuronides after i.v.-infusion of morphine and morphine-6-glucuronide in healthy volunteers. Clin Pharmacol Ther 1996; 60:316-25
30. Hanna MH, Peat SJ, Woodham M, Knibb A, Fung C: Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: Comparison with morphine. Br J Anaesth 1990; 64:547-50
31. Grace D, Fee JP: A comparison of intrathecal morphine-6-glucuronide and intrathecal morphine sulfate as analgesics for total hip replacement. Anesth Analg 1996; 83:1055-9
32. Osborne R, Thompson P, Joel S, Trew D, Patel N, Slevin M: The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 1992; 34:130-8
33. Portenoy RK, Khan E, Layman M, Lapin J, Malkin MG, Foley KM, Thaler HT, Cerbone DJ, Inturrisi CE: Chronic morphine therapy for cancer pain: Plasma and cerebrospinal fluid morphine and morphine-6-glucuronide concentrations. Neurology 1991; 41:1457-61
34. Bickel U, Schumacher O, Kang YS, Voigt K: Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat. J Pharmacol Exp Ther 1996; 278:107-13
35. Kramer TH, d'Amours RH, Buettner BS: Pharmacodynamic model of the effects of morphine-6-glucuronide during patient-controlled analgesia. Clin Pharmacol Ther 1996; 59:132
36. Murphey LJ, Olsen GD: Diffusion of morphine-6-beta-D-glucuronide into the neonatal guinea pig brain during drug-induced respiratory depression. J Pharmacol Exp Ther 1994; 271:118-24
37. Aasmundstad TA, Morland J, Paulsen RE: Distribution of morphine 6-glucuronide and morphine across the blood-brain barrier in awake, freely moving rats investigated by in vivo microdialysis sampling. J Pharmacol Exp Ther 1995; 275:435-41
38. Steen KH, Anton F, Reeh PW, Handwerker HO: Sensitization and selective excitation by protones of nociceptive nerve endings in rat skin, in vitro. Pflügers Arch 1990; 415:R106
39. Thürauf N, Hummel T, Kettenmann B, Kobal G: Nociceptive and reflexive responses recorded from the human nasal mucosa. Brain Res 1993; 629:293-9
40. Glare PA, Walsh TD: Clinical pharmacokinetics of morphine. Ther Drug Monit 1991; 13:1-23
41. Dahlstrom B, Tamsen A, Paalzow L, Hartvig P: Patient-controlled analgesic therapy. Part IV: Pharmacokinetics and analgesic plasma concentrations of morphine. Clin Pharmacokinetic 1982; 7:266-79
42. Kobal G, Hummel C, Nuernberg B, Brune K: Effects of pentazocine and acetylsalicylic acid on pain-rating, pain-related evoked potentials and vigilance in relationship to pharmacokinetic parameters. Agents Actions 1990; 29:342-59
43. Kobal G: Pain-related electrical potentials of the human nasal mucosa elicited by chemical stimulation. Pain 1985; 22:151-63
44. Venn RF, Michalkiewicz A: Fast reliable assay for morphine and its metabolites using high-performance liquid chromatography and native fluorescence detection. J Chromatogr 1990; 525:379-88
45. Hartley R, Green M, Quinn M, Levene MI: Analysis of morphine and its 3- and 6-glucuronides by high performance liquid chromatography with fluorimetric detection following solid phase extraction from neonatal plasma. Biomed Chromatogr 1993; 7:34-7
46. Bromm B, Ganzel R, Herrmann WM, Meier W, Scharein E: The analgesic efficacy of flupirtine in comparison to pentazocine and placebo assessed by EEG and subjective pain ratings. Postgrad Med J 1987; 63(Suppl 3):109-12
47. Schmidt N, Brune K, Geisslinger G: Opioid receptor agonist potencies of morphine and morphine-6- glucuronide in the guinea-pig ileum. Eur J Pharmacol 1994; 255:245-7
48. Thompson PI, Hucks D, McLoughlin L, Grossman A, Rees L, Slevin M: Comparative opiate receptor affinities of morphine and its active metabolite morphine-6-glucuronide. Br J Cancer 1990; 62:484
49. Oguri K, Yamada Mori I, Shigezane J, Hirano T, Yoshimura H: Enhanced binding of morphine and nalorphine to opioid delta receptor by glucuronate and sulfate conjugations at the 6-position. Life Sci 1987; 41:1457-64
50. Chen ZR, Irvine RJ, Somogyi AA, Bochner F: Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991; 48:2165-71
51. Pasternak GW: Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol 1993; 16:1-18
52. Pasternak GW: Multiple morphine and enkephalin receptors: biochemical and pharmacological aspects. Ann N Y Acad Sci 1986; 467:130-9
53. Hanks GW, Hoskin PJ, Aherne GW, Turner P, Poulain P: Explanation for potency of repeated oral doses of morphine? Lancet 1987; 2:723-5
54. Wahlstrom A, Winblad B, Bixo M, Rane A: Human brain metabolism of morphine and naloxone. Pain 1988; 35:121-7
55. Bodenham A, Quinn K, Park GR: Extrahepatic morphine metabolism in man during the anhepatic phase of orthotopic liver transplantation. Br J Anaesth 1989; 63:380-4
56. 2 pulses applied to the nasal mucosa. Pain 1992; 49:53-60
57. Chen AC, Chapman CR, Harkins SW: Brain evoked potentials are functional correlates of induced pain in man. Pain 1979; 6:365-74
58. Chudler EH, Dong WK: The assessment of pain by cerebral evoked potentials. Pain 1983; 16:221-44
59. Carmon A, Dotan Y, Sarne Y: Correlation of subjective pain experience with cerebral evoked responses to noxious thermal stimulations. Exp Brain Res 1978; 33:445-53
60. Chapman CR: Evoked potentials as correlates of pain and pain relief in man. Agents Actions Suppl. 1986; 19:51-73
61. Huttunen J, Kobal G, Kaukoranta E, Hari R: Cortical responses to painful CO2 stimulation of nasal mucosa; A magnetoencephalographic study in man. Electroencephalogr Clin Neurophysiol 1986; 64:347-9
62. Chudler EH, Dong WK, Kawakami Y: Tooth pulp evoked potentials in the monkey: cortical surface and intracortical distribution. Pain 1985; 22:221-3
63. Hummel T, Hummel C, Friedel I, Pauli E, Kobal G: A comparison of the antinociceptive effects of imipramine, tramadol and anpirtoline. Br J Clin Pharmacol 1994; 37:325-33
64. Thürauf N, Ditterich W, Kobal G: Dose-related effects of a benzodiazepine on event-related potentials elicited by painful stimuli in man. Br J Clin Pharmacol 1994; 38:545-56
65. Kobal G, Hummel T: Effects of flupirtine on the pain-related evoked potential and the spontaneous EEG. Agents Actions 1988; 23:117-9
66. Kobal G, Hummel T, Hoesl M: Pain-related electrical evoked potentials by chemical stimuli: Effects of fentanyl, Advances in Pain Research and Therapy. Edited by S Lipton, E Tunks, M Zoppi. New York, Raven Press, 1989, pp 95-8
67. Kobal G, Hummel C, Gruber M, Geisslinger G, Hummel T: Dose-related effects of ibuprofen on pain-related potentials. Br J Clin Pharmacol 1994; 37:445-52
68. Lötsch J, Geisslinger G, Mohammadian P, Brune K, Kobal G: Effects of flurbiprofen enantiomers on pain-related chemo-somatosensory evoked potentials in human subjects. Br J Clin Pharmacol 1995; 40:339-46
69. Thürauf N, Fleischer WK, Liefhold J, Schmid O, Kobal G: Dose dependent time course of the analgesic effect of a sustained-release preparation of tramadol on experimental phasic and tonic pain. Br J Clin Pharmacol 1996; 41:115-23
70. Foley KM: The treatment of cancer pain. N Engl J Med 1985; 313:84-95